RSS-Feed abonnieren
DOI: 10.1055/s-0031-1296625
Pharmacokinetics and Bioequivalence Study of Ranitidine Film Tablets in Healthy Male Subjects
Publikationsverlauf
Publikationsdatum:
21. Dezember 2011 (online)
![](https://www.thieme-connect.de/media/amf/200706/lookinside/thumbnails/10.1055-s-0031-1296625-1.jpg)
Abstract
The aim of the present study was to compare the bioavailability of ranitidine (CAS 66357-35-5) from two different ranitidine hydrochloride (CAS 66357-59-3) film tablets (Ranitab© 150 mg film tablets as test preparation and 150 mg film tablets of the originator product as reference preparation). The study was conducted according to an open-label, randomised two-period cross-over design with a wash-out phase of 9 days.
Blood samples for pharmacokinetic profiling were taken up to 24 h post-dose, and ranitidine plasma concentrations were determined with a validated HPLC method with UV-detection.
Maximum plasma concentrations (Cmax) of 461.8 ng/ml (test) and 450.6 ng/ ml (reference) were achieved. Areas under the plasma concentration-time curve (AUC0→∞ of 2,488.6 ng · h/ml (test) and 2,528.8 ng · h/ml (reference) were calculated. The median tmax was 2.83 h (test) and 3.04 h (reference). Plasma elimination half-lives (t1/2) of 2.78 h (test) and 2.89 h (reference) were determined. Both primary target parameters AUC0→∞ and Cmax were tested parametrically by analysis of variance (ANOVA) and the 90% confidence intervals were between 91.93%-106.98% (AUC0→∞) and 92.34%-l18.85% (Cmax). Bioequivalence between test and reference preparation was demonstrated since for both parameters AUC and Cmax the 90% confidence intervals of the T/R ratios of logarithmically transformed data were in the generally accepted range of 80%-125%.